Duke Capital Limited (DUKE) — Investment Research Note

Executive summary

Duke Capital is a Guernsey-listed AIM provider of "hybrid capital" — long-dated, low-amortising senior-secured loans (typically 25–30-year "corporate mortgages") combined with minority equity stakes — to profitable, owner-managed SMEs in the UK, Ireland and North America. Across the five-year period covered by the filings the company has grown recurring cash revenue from £15m (FY22) to £25.8m (FY25), maintained a 2.80p dividend through Covid and 2022–24 interest-rate stress, but FY25 marked a clear cooling: no investment exits, a £14m fair-value writedown on the portfolio, free cash flow per share fell from 4.34p to 2.83p, and Q1/Q2 FY26 recurring revenue is flat-to-low-single-digit growth. The single most important point for valuation today is that the shares trade at ~0.74x last reported NAV (177.6m equity vs £131.3m market cap), with the discount reflecting AIM small-cap illiquidity, level-3 portfolio marks and a dividend that — while currently covered by recurring FCF — is no longer comfortably so.

Fair value estimate

• Methodology: NAV-anchored cross-check with a dividend-yield triangulation. Duke is a yield/credit vehicle, not an earnings compounder, so NAV (with a discount for AIM scale and level-3 valuation risk) plus a peer dividend-yield check is more appropriate than a forward P/E or DCF.
• NAV approach: FY25 net assets £177.6m / 502.2m external shares = ~35.4p per share. Applying a 15–20% discount for AIM illiquidity, level-3 valuation opacity and the recent FCF deterioration → 28–30p.
• Dividend yield approach: 2.80p annual dividend at a 7.5–9.0% target yield (consistent with listed peers Real Estate Credit Investments, BioPharma Credit, GCP Asset Backed) → 31–37p.
• Fair value range: 30p – 36p per share, midpoint ~33p
• Implied market cap range: £151m – £181m, midpoint ~£166m
• Current market cap £131.3m → ~26% upside to mid, with a 15% margin of safety to the low end
• View: undervalued, but only modestly, and not from an AI-thesis angle

Sector context

• ICB classification confirmed: Financials / Financial Services / specialty lending.
• Profile vs peers: Above-typical yield (10.7% trailing) reflects perceived risk; gross margins of a credit book are not directly comparable, but cost ratio (£4.7m opex on £25.8m recurring revenue = 18%) is healthy for the scale. Leverage 3.3x net debt to recurring cash revenue is moderate by private-credit standards.
• Closest listed peers: Real Estate Credit Investments (RECI), BioPharma Credit (BPCR), GCP Asset Backed Income — all closed-end private-credit vehicles trading at discounts to NAV with high dividend yields. Duke is more concentrated (14 partners) and has equity-upside optionality that pure credit funds lack.

Investment thesis

1. Discount-to-NAV with covered dividend gives a ~10–11% yield while waiting for exits to crystallise embedded value. Portfolio fair value of £244m, equity stakes in 12 partners marked at EBITDA multiples of 4.3–7.9x — historically Duke has exited at higher multiples (Fabrikat: 3-year IRR with triple-digit return; BHP IRR 29%; Instor triple-digit IRR). 2025-06 FY25 final results; 2023-07 FY23 final results
2. Capital-light, fixed-cost operating model with operational leverage on each new deployment. FY25 fixed opex grew just 5% on flat headcount while recurring revenue grew 6%. Each marginal £1 of recurring revenue carries near-100% incremental margin once the fixed Guernsey overhead and Fairfax interest bill is covered. 2025-06 FY25 final results
3. Macroeconomic tailwind from rate cuts and bank retreat from lower mid-market SME lending. Management has flagged the SONIA-linked Fairfax facility (cost SONIA+5%) materially benefits as UK base rates fall (already cut to 4.25% in May 2025); concurrently bank withdrawal leaves an underserved SME segment that suits Duke's product. 2025-06 FY25 final results; 2025-09 Q2 FY26 trading update

Key risks

1. Free cash flow has materially deteriorated — FY25 FCF per share fell 35% to 2.83p versus a 2.80p dividend, meaning the dividend is barely covered on a recurring basis without exits. Continued absence of exits would force a dividend cut. 2025-06 FY25 final results
2. Portfolio fair-value risk is concentrated and opaque — all £244m of investments are level-3 valued using discounted cash flow with unobservable inputs (discount rates 7.2–17.7%, EBITDA multiples 4.3–7.9x). FY25 took an £8.2m loss on hybrid credit assets and £5.9m loss on equity, reversing prior gains. With 14 partners only, single-investment write-downs swing reported earnings sharply. 2025-06 FY25 final results
3. Equity raise dilution and ongoing third-party-funding execution risk — Duke raised £23.5m at 27.5p in Nov 2024 and £20m at 35p in May 2022, both at discounts to NAV. The stated strategy to access non-dilutive third-party JV/managed-account capital has been promised since 2024 but remains unconcluded, so further equity dilution remains the funding bridge. 2024-12 interim results; 2025-06 FY25 final results

Operating leverage

Duke has moderate operating leverage. The fixed-cost base is small (~£4.7m administrative and personnel + £1.0m legal/professional/other = ~£5.7m total, including £0.7m support-services fees to related parties Abingdon and Arlington) versus £25.8m recurring revenue, so the operating margin is already high (~80%). The constraint is that incremental revenue requires incremental capital deployment — every new £10m of deployments yields roughly £1.3m of recurring revenue at the current ~13% yield, but consumes equity or debt capacity. The pure fixed-cost lever therefore caps at the existing cost base: a 10–20% beat in revenue from the current portfolio (e.g. via inflation-linked annual adjustments) would drop almost entirely to FCF and could lift FCF per share by 15–25%. However, large surprises in revenue won't deliver multiples-of-profit upside because each new partner requires fresh capital. The bigger upside lever is exits: a single £20m exit at a 20% IRR uplift can swing total cash revenue by 15–20% in a single year. 2025-06 FY25 final results

Value-trap signals

• Dividend not raised in three years despite portfolio growth — payout is stuck at 2.80p since FY23.
• FCF per share declining (FY24 4.34p → FY25 2.83p), reversing the prior trend.
• Repeated equity raises at discounts to NAV (Nov 2024 at 27.5p; May 2022 at 35p), suggesting limited access to growth capital except via dilution.
• Stated third-party non-dilutive funding strategy has been "in progress" since 2024 with no closed deal.
• Heavy related-party transactions (~£0.7m p.a. to Abingdon/Arlington, both director-affiliated).
• Concentrated AIM share register with low daily liquidity.

Earnings vs expectations

Across the trading updates, Duke consistently provides quarterly guidance one quarter ahead, and the results have largely met guidance — Q1 FY26 expected £6.6m (delivered as guided), Q2 FY26 guided £6.6m (3% YoY growth, in line). Pre-Covid quarters saw consistent sequential growth (Q1 FY23 £5.1m → Q1 FY24 £6.0m → Q1 FY26 £6.6m). However, the trajectory has slowed: 70% recurring revenue growth in FY22 → 46% FY23 → 12% FY24 → 6% FY25. Adjusted EPS missed the implicit FY24 run-rate, falling 28% to 3.48p in FY25. Net income missed by a wide margin due to non-cash fair-value swings (FY25 PAT £2.0m vs £11.6m in FY24). Pattern: operationally meets guidance but the reported earnings line has been volatile due to portfolio fair-value movements, and growth has decelerated meaningfully.

Conviction

Conviction: 3 (moderate)

Anchored by: (i) the NAV figure is well-disclosed and audited with detailed sensitivity tables; (ii) the dividend yield/NAV-discount methodology converges on a tight 30–36p range; (iii) management discloses recurring vs non-recurring cash revenue cleanly.

Limited by: (i) £244m of level-3 portfolio assets where small changes to discount rates (±25bp = ±£2.3m) or EBITDA multiples (±0.25x = ±£1.8m) materially change NAV — I cannot independently verify the marks; (ii) timing of exits (the main upside lever) is genuinely unpredictable.